• 05 May 20

Shield Therapeutics 'very active' on US partnering discussions with significant interest

Shield Therapeutics 'very active' on US partnering discussions with significant interest

Shield Therapeutics Plc | STX | 10.1 -0.15 (0.0%)

    • 101 views

 

Shield Therapeutics (LON:STX) CEO Tim Watts tells Proactive London's Andrew Scott they've seen very little disruption from the coronavirus pandemic on plans to commercialise its iron deficiency drug Feraccru.

He says talks to find a partner for the product in the US are ongoing with significant interest from a range of companies.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Shield Therapeutics doubles Q2 revenue and sets sights on 2025 profitability with ACCRUFeR momentum

Companies: Shield Therapeutics Plc

Shield Therapeutics extends cash runway into 2021 after significant China deal

Companies: Shield Therapeutics Plc

Shield Therapeutics doubles Q2 revenue and sets sights on 2025 profitability with ACCRUFeR momentum

Companies: Shield Therapeutics Plc

Shield Therapeutics remain optimistic about US commercialisation of Accrufer in the US

Companies: Shield Therapeutics Plc

Shield Therapeutics Eyes Cash Flow Positive Target by 2025

Companies: Shield Therapeutics Plc

Shield Therapeutics' on cusp of US market expansion with focus on commercialising Accrufer

Companies: Shield Therapeutics Plc

© Research Tree 2026

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top